European CHMP recommends approval of generic formulation of icatibant

Icatibant Accord, available as a 30 mg solution for injection, is a generic of Firazyr, and will be licensed for symptomatic treatment of acute attacks of hereditary angioedema in adults, adolescents and children aged 2 years and older, with C1‑esterase‑inhibitor deficiency.

Source:

European Medicines Agency